Zosano Pharma (Zosano Pharma) Float Percentage Of Total Shares Outstanding : 98.36% (As of Apr. 29, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Zosano Pharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Zosano Pharma's float shares is 4.82 Mil. Zosano Pharma's total shares outstanding is 4.90 Mil. Zosano Pharma's float percentage of total shares outstanding is 98.36%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Zosano Pharma's Insider Ownership is 29.52%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Zosano Pharma's Institutional Ownership is 0.30%.

Zosano Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Zosano Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	4.82	/	4.90
	=	98.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zosano Pharma (Zosano Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zosano Pharma Corp (OTCPK:ZSANQ) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

34790 Ardentech Court, Fremont, CA, USA, 94555

Website

https://www.zosanopharma.com

Zosano Pharma Corp is a clinical-stage biopharmaceutical company. It is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using the proprietary transdermal microneedle system. The system is designed to facilitate rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. The company's operating segment is to develop human pharmaceutical products. Its primary product candidate is Qtrypta (M207) which is the proprietary formulation of zolmitriptan delivered utilizing the system.

Executives

Christine Matthews	officer: Chief Financial Officer	C/O ZOSANO PHAMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Steven Lo	director, officer: Chief Executive Officer	C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94010
Donald J Kellerman	officer: VP, Clinical Dev & Med Affairs	INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Elaine Yang	director	C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Kenneth Greathouse	director	3260 WHIPPIE ROAD, UNION CITY CA 94587
Hayley Lewis	officer: See Remarks	C/O CARBYLAN THERAPEUTICS, INC., 3181 PORTER DRIVE, PALO ALTO CA 94304
Kathy M. Mcgee	director	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Linda S Grais	director	86 ALEJANDRA AVE, ATHERTON CA 94027
Joseph P Hagan	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Kleanthis G Xanthopoulos	director	9050 CAMINO SANTA FE, SAN DIEGO CA 92121
John Peter Walker	director	126 ISABELLA AVE, ATHERTON CA 94027
Aisling Capital Partners Iv, Lp	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Partners Iv Llc	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Iv, Lp	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff	10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022